Higher Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Anti-Angiogenic Agents

REFERENCES

• Weitzman R., Sauter N., Eriksen E. F., Tarassoff P. G., Lacerna L. V., Dias R., et al. Critical review: Updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients—May 2006. Crit Rev Oncol Hematol 2007; 62(2)148–152
   PubMed Web of Science ®Google Scholar
• Marx R. E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 2003; 61(9)1115–1117
   PubMed Web of Science ®Google Scholar
• Ruggiero S. L., Mehrotra B., Rosenberg T. J., Engroff S. L. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 2004; 62(5)527–534
   PubMed Web of Science ®Google Scholar
• Bagan J., Blade J., Cozar J. M., Constela M., Garcia Sanz R., Gomez Veiga F., et al. Recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates. Med Oral Pathol Oral Cir Bucal 2007; 12(4)E336–340
   PubMedGoogle Scholar
• Burr D. B. Summary of ASBMR Task Force on ONJ. J Musculoskelet Neuronal Interact 2007; 7(4)354–355
   PubMedGoogle Scholar
• Schwartz H. C. Osteonecrosis of the jaws: A complication of cancer chemotherapy. Head Neck Surg 1982; 4(3)251–253
   PubMedGoogle Scholar
• Marx R. E., Sawatari Y., Fortin M., Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005; 63(11)1567–1575
   PubMed Web of Science ®Google Scholar
• Woo S.-B., Hellstein J. W., Kalmar J. R. Systematic Review: Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006; 144(10)753–761
   PubMed Web of Science ®Google Scholar
• Woo S. B., Hande K., Richardson P. G. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005; 353(1)99–102, discussion 199–102
   PubMed Web of Science ®Google Scholar
• Wang J., Goodger N. M., Pogrel M. A. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 2003; 61(9)1104–1107
   PubMed Web of Science ®Google Scholar
• Marymont J. V., Kaufman E. E. Osteonecrosis of bone associated with combination chemotherapy without corticosteroids. Clin Orthop Relat Res 1986; 204: 150–153
   PubMedGoogle Scholar
• Obrist R., Hartmann D., Obrecht J. P. Osteonecrosis after chemotherapy. Lancet 1978; 1(8077)1316
   PubMed Web of Science ®Google Scholar
• Estilo C. L., Van Poznak C. H., Williams T., Evtimovska E., Tkach L., Halpern J. L., et al. Osteonecrosis of the maxilla and mandible in patients treated with bisphosphonates: A retrospective study. J Clin Oncol (Meeting Abstracts) 2004; 22(14_suppl)8088
   Google Scholar
• Bamias A., Kastritis E., Bamia C., Moulopoulos L. A., Melakopoulos I., Bozas G., et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005; 23(34)8580–8587
   PubMed Web of Science ®Google Scholar
• Ning Y. M., Gulley J., Arlen P., Latham L., Srinavasan R., Wright J., et al. A phase II trial of thalidomide, bevacizumab, and docetaxel in patients (pts) with metastatic castration-refractory prostate cancer (CRPC). ASCO Genitourinary Cancers Symposium, San Francisco, 2008, Abstract # 164
   Google Scholar
• Cavanna L., Berte R., Arcari A., Mordenti P., Pagani R., Vallisa D. Osteonecrosis of the jaw. A newly emerging site-specific osseous pathology in patients with cancer treated with bisphosphonates. Report of five cases and review of the literature. Eur J Intern Med 2007; 18(5)417–422
   PubMed Web of Science ®Google Scholar
• Mashiba T., Mori S., Burr D. B., Komatsubara S., Cao Y., Manabe T., et al. The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib. J Bone Miner Metab 2005; 23(Suppl)36–42
   PubMed Web of Science ®Google Scholar
• Scavelli C., Di Pietro G., Cirulli T., Coluccia M., Boccarelli A., Giannini T., et al. Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma. Mol Cancer Ther 2007; 6(12)3256–3262
   PubMed Web of Science ®Google Scholar
• Santini D., Caraglia M., Vincenzi B., Holen I., Scarpa S., Budillon A., et al. Mechanisms of disease: Preclinical reports of antineoplastic synergistic action of bisphosphonates. Nat Clin Pract Oncol 2006; 3(6)325–338
   PubMedGoogle Scholar
• Ferretti G., Fabi A., Carlini P., Papaldo P., Felici A., Tomao S., et al. Zoledronic acid and angiogenesis. Clin Cancer Res 2007; 13: 6850, (22 Pt 1); author reply 6850–6851
   PubMed Web of Science ®Google Scholar
• Wood J., Bonjean K., Ruetz S., Bellahcene A., Devy L., Foidart J. M., et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002; 302(3)1055–1061
   PubMed Web of Science ®Google Scholar
• Fournier P., Boissier S., Filleur S., Guglielmi J., Cabon F., Colombel M., et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002; 62(22)6538–6544
   PubMed Web of Science ®Google Scholar
• Garcia Saenz J. A., Lopez Tarruella S., Garcia Paredes B., Rodriguez Lajusticia L., Villalobos L., Diaz Rubio E. Osteonecrosis of the jaw as an adverse bisphosphonate event: Three cases of bone metastatic prostate cancer patients treated with zoledronic acid. Med Oral Pathol Oral Cir Bucal 2007; 12(5)E351–356
   PubMedGoogle Scholar
• Wang E. P., Kaban L. B., Strewler G. J., Raje N., Troulis M. J. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J Oral Maxillofac Surg 2007; 65(7)1328–1331
   PubMed Web of Science ®Google Scholar
• Ortega C., Faggiuolo R., Vormola R., Montemurro F., Nanni D., Goia F., et al. Jaw complications in breast and prostate cancer patients treated with zoledronic acid. Acta Oncol 2006; 45(2)216–217
   PubMed Web of Science ®Google Scholar
• Ortega C., Montemurro F., Faggiuolo R., Vormola R., Nanni D., Goia F., et al. Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: A retrospective analysis. Acta Oncol 2007; 46(5)664–668
   PubMed Web of Science ®Google Scholar
• Saad F., Gleason D. M., Murray R., Tchekmedyian S., Venner P., Lacombe L., et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94(19)1458–1468
   PubMed Web of Science ®Google Scholar
• Aapro M., Abrahamsson P. A., Body J. J., Coleman R. E., Colomer R., Costa L., et al. Guidance on the use of bisphosphonates in solid tumours: Recommendations of an international expert panel. Ann Oncol 2008; 19(3)420–432
   PubMed Web of Science ®Google Scholar
• Zervas K., Verrou E., Teleioudis Z., Vahtsevanos K., Banti A., Mihou D., et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: A single-centre experience in 303 patients. Br J Haematol 2006; 134(6)620–623
   PubMed Web of Science ®Google Scholar
• Durie B. G.M., Katz M., Crowley J., Woo S.-B., Hande K., Richardson P. G., et al. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005; 353(1)99–102
   PubMed Web of Science ®Google Scholar
• Zanglis A., Andreopoulos D., Dima M., Baltas G., Baziotis N. Jaw uptake of technetium-99 methylene diphosphonate in patients on biphosphonates: A word of caution. Hell J Nucl Med 2007; 10(3)177–180
   PubMed Web of Science ®Google Scholar
• Chiandussi S., Biasotto M., Dore F., Cavalli F., Cova M. A., Di Lenarda R. Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws. Dentomaxillofac Radiol 2006; 35(4)236–243
   PubMed Web of Science ®Google Scholar
• Khan S. A., Kanis J. A., Vasikaran S., Kline W. F., Matuszewski B. K., McCloskey E. V., et al. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res 1997; 12(10)1700–1707
   PubMed Web of Science ®Google Scholar